• Mitglied der Deutschen Gesellschaft für Hämatologie und Onkologie und der Deutschen Gesellschaft für Innere Medizin 

• Weiterbildungsermächtigung für Hämatologie/Onkologie

• Facharzt für Innere Medizin, Hämatologie und Onkologie

1: Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B,

Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B,

Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K,

Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M,

Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC;

German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of

isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy

for newly diagnosed, transplantation-eligible patients with multiple myeloma

(GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled,

phase 3 trial. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi:

10.1016/S2352-3026(22)00263-0. PMID: 36328040.

2: Giagounidis AAN, Heinsch M, Kasperk R, Aul C. Fournier's gangrene. Ann

Hematol. 2003 Aug;82(8):531-532. doi: 10.1007/s00277-003-0688-z. Epub 2003 Jun

14. PMID: 12811517.

3: Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J,

Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz

C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A,

Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C,

Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-

speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Elotuzumab,

lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell

transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a

randomised, phase 3 trial. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi:

10.1016/S2352-3026(23)00366-6. Erratum in: Lancet Haematol. 2024 Mar;11(3):e181.

doi: 10.1016/S2352-3026(24)00036-X. PMID: 38302221.

4: Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C. Acute

basophilic leukemia. Eur J Haematol. 2001 Aug;67(2):72-6. doi:

10.1034/j.1600-0609.2001.t01-1-00487.x. PMID: 11722593.

5: Stratmann JA, von Rose AB, Koschade S, Wendelin K, Köhler F, Heinsch M,

Schiller K, Haferlach C, Wattad M, Rieder H, Serve H, Gökbuget N, Steffen B.

Clinical and genetic characterization of de novo double-hit B cell precursor

leukemia/lymphoma. Ann Hematol. 2019 Mar;98(3):647-656. doi:

10.1007/s00277-018-03590-x. Epub 2019 Jan 6. PMID: 30613837.

6: Buck AK, Grigoleit GU, Kraus S, Schirbel A, Heinsch M, Dreher N, Higuchi T,

Lapa C, Hänscheid H, Samnick S, Einsele H, Serfling SE, Werner RA. C-X-C Motif

Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced

T-Cell Lymphoma. J Nucl Med. 2023 Jan;64(1):34-39. doi:

10.2967/jnumed.122.264207. Epub 2022 Jun 23. PMID: 35738903; PMCID: PMC9841250.

7: Boquoi A, Giagounidis A, Goldschmidt H, Heinsch M, Rummel MJ, Kröger N, Mai

EK, Strapatsas J, Haas R, Kobbe G. Health-Related Quality of Life in Multiple

Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy

after Autologous Stem Cell Transplantation-Results from the LenaMain Trial

(NCT00891384). Cancers (Basel). 2023 Oct 26;15(21):5157. doi:

10.3390/cancers15215157. PMID: 37958331; PMCID: PMC10650513.

8: Aul C, Giagounidis A, Heinsch M, Germing U, Ganser A. Prognostic indicators

and scoring systems for predicting outcome in patients with myelodysplastic

syndromes. Rev Clin Exp Hematol. 2004 Dec 1;8(2):E1. PMID: 16027099.

9: Giagounidis AA, Hildebrandt B, Braunstein S, Aivado M, Germing U, Heinsch M,

Aul C. Testicular infiltration in acute myeloid leukemia with complex karyotype

including t(8;21). Ann Hematol. 2002 Feb;81(2):115-8. doi:

10.1007/s00277-001-0396-5. Epub 2001 Dec 8. PMID: 11907795.

10: Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C. Autoimmune disorders

in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol.

2005;113(2):146-9. doi: 10.1159/000083454. PMID: 15802895.

11: Giagounidis AA, Heinsch M, Haase S, Aul C. Early plasmacytoid dendritic cell

leukemia/lymphoma coexpressing myeloid antigenes. Ann Hematol. 2004

Nov;83(11):716-21. doi: 10.1007/s00277-004-0913-4. Epub 2004 Aug 5. PMID:

15316755.

12: Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch

C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C. Clinical, morphological,

cytogenetic, and prognostic features of patients with myelodysplastic syndromes

and del(5q) including band q31. Leukemia. 2004 Jan;18(1):113-9. doi:

10.1038/sj.leu.2403189. PMID: 14586479.

13: Fenk R, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kroger N, Boquoi

A, Lopez D, Gerrlich C, Baier J, Liesenjohann S, Hauck K, Savickaite I, Mai EK,

Aul C, Strapatsas J, Dienst A, Kondakci M, Haas R, Kobbe G. Efficacy and

Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of

Multiple Myeloma after Autologous Blood Stem Cell Transplantation. Clin Cancer

Res. 2020 Nov 15;26(22):5879-5886. doi: 10.1158/1078-0432.CCR-20-0841. Epub 2020

Aug 17. PMID: 32817078.

14: Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C.

Prognosis of patients with del(5q) MDS and complex karyotype and the possible

role of lenalidomide in this patient subgroup. Ann Hematol. 2005

Sep;84(9):569-71. doi: 10.1007/s00277-005-1054-0. Epub 2005 May 13. PMID:

15891887.

15: Russwurm G, Heinsch M, Radkowski R, Erlemann R, Aul C, Haase S, Giagounidis

A. Dasatinib induces complete remission in a patient with primary cerebral

involvement of B-cell chronic lymphocytic leukemia failing chemotherapy. Blood.

2010 Oct 7;116(14):2617-8. doi: 10.1182/blood-2010-04-279786. PMID: 20930084.

16: Giagounidis AA, Heinsch M, von Barany RU, Erlemannb R, Aul C. Breast cancer

metastasis to the aortic vessel wall. Onkologie. 2005 Jun;28(6-7):369. doi:

10.1159/000085715. PMID: 15973777.

17: Giagounidis AA, Haase S, Heinsch M, Göhring G, Schlegelberger B, Aul C.

Lenalidomide in the context of complex karyotype or interrupted treatment: case

reviews of del(5q)MDS patients with unexpected responses. Ann Hematol. 2007

Feb;86(2):133-7. doi: 10.1007/s00277-006-0217-y. Epub 2006 Nov 17. PMID:

17111142; PMCID: PMC1705486.

18: Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G,

Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A,

Aivado M, Heinsch M, Aul C. Treatment of myelodysplastic syndrome with isolated

del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid

and tocopherol-alpha: a phase II study. Ann Hematol. 2005 Jun;84(6):389-94. doi:

10.1007/s00277-005-1027-3. Epub 2005 Mar 23. PMID: 15785949.

19: Oehme A, Heinsch M. Vergleich chlamydienserologischer Tests unter besonderer